Clinical Study of Paricalcitol in the Treatment of Secondary Hyperparathy-roidism in Hemodialysis Patients
Objective To investigate the effect of paricalcitol on secondary hyperparathyroidism in hemodialysis pa-tients.Methods A total of 72 patients with secondary hyperparathyroidism diagnosed and treated in Danyang Third People's Hospital from January 2020 to December 2022 were selected as the study objects and were divided into two groups by random number table method.The control group(n=36)was treated with calcitriol,and the observation group(n=36)was treated with paricalcitol.The clinical efficacy was evaluated after 12 weeks of treatment.Calcium and phosphorus metabolism and parathyroid hormone levels were compared before and after treatment,and inflamma-tory response was evaluated.Results The total effective rate of the observation group was higher than that of the con-trol group,the difference was statistically significant(P＜0.05).After treatment,blood calcium(2.31±0.24)mmol/L,blood phosphorus(1.84±0.22)mmol/L and parathyroid hormone(365.25±84.61)pg/mL in observation group were lower than those in control group,the differences were statistically significant(t=3.635,4.605,7.409,all P＜0.05).Af-ter treatment,the level of inflammatory factors in observation group was lower than those in control group,the differ-ence was statistically significant(P＜0.05).Conclusion In patients with secondary hyperparathyroidism caused by he-modialysis,palicalcitol can improve calcium and phosphorus metabolism and parathyroid hormone levels,and reduce inflammation.
Parathyroid glandsHyperfunctionHemodialysisParicalcitolCalcitriolCalcium and phosphorus metabolism
NETL
NSTL
万方数据
